NCT06327685 2026-01-08
Avapritinib With Decitabine in Patients With SM-AHN
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
Clinical Trials
9 trialsNCT07131059 2025-08-20
MRD-positive AML Clinical Study
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Recruiting
NCT03580655 2025-04-30
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Blueprint Medicines Corporation
Phase 2 Completed
NCT06783790 2025-01-20
Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT06765915 2025-01-09
Avapritinib Maintenance for AML With KIT Mutations
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06221683 2024-08-22
GMCAII
Children's Hospital of Soochow University
Phase 2 Recruiting
NCT06316960 2024-08-22
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
Children's Hospital of Soochow University
Phase 2 Recruiting
NCT05821738 2023-05-09
Avapritinib in CBF-AML With KIT Mutations
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT02561988 2023-03-17
(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
Blueprint Medicines Corporation
Phase 1 Completed